Friday, March 23, 2012
Euthymics Bioscience Inc., of Cambridge, Mass., said it started a Phase I trial of EB-1020, a next-generation drug in development for treating adult attention deficit hyperactivity disorder aimed at carrying a low risk of drug abuse liability.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.